Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Curr Drug Deliv ; 20(6): 830-840, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36698231

RESUMEN

BACKGROUND: Ketorolac tromethamine (KT) is a non-steroidal anti-inflammatory drug from the heteroaryl acetic acid derivatives family. The most widely used new nanotechnological approaches for topical drug delivery are polymeric nanoparticles (NPs). OBJECTIVE: Successful results have been obtained with low doses in many treatments, such as cancer, antimicrobial, pain, made with nanoparticle formulations of drug active ingredients. METHODS: NPs were prepared using Nano Spray-Dryer. The cytotoxicity of the optimum formulation in BJ (ATCC® CRL-2522™) human fibroblast cells was determined by the WST- 1 method and the gene activity was elucidated by mRNA isolation and real-time polymerase chain reaction (RT-PCR). The in vivo HET- CAM assay was performed for anti-inflammatory activity. RESULTS: NPs presented PDI values lower than 0.5, and therefore particle size distribution was decided to be monodisperse. Positive zeta potential values of NPs highlighted the presence of the cationic ammonium group of Eudragit® RS 100. The release rates observed from KT-NP coded formulations after 24 hours were 78.4% ± 2.9, demonstrating extended release from all formulations, relative to pure KT. The lowest concentration of KT-NP increased fibroblast cell proliferation higher than the highest concentration of KT. The 5-fold increased effect of KT-NP formulation on collagen gene expression compared to KT is also related to the enhanced anti-inflammatory effect in line with the in vivo HET-CAM assay results. CONCLUSION: With the obtained cell viability, gene expression, and HET-CAM results, it has the hope of a successful nano-topical formulation, especially in both wound healing and anti-inflammatory treatment.


Asunto(s)
Ketorolaco Trometamina , Nanopartículas , Humanos , Antiinflamatorios no Esteroideos/farmacología , Supervivencia Celular , Sistemas de Liberación de Medicamentos/métodos
2.
Pharmazie ; 70(2): 67-73, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25997244

RESUMEN

In the present study chitosan based gel formulations containing Egg Yolk Oil (EYO) and Epidermal Growth Factor (EGF) were formulated successfully aiming at enhanced topical treatment of dermal burns the combination of traditional approaches with modern drug delivery systems. Physicochemical properties of the formulations were analyzed and efficacy of the formulations prepared were evaluated versus a commercial product; Silverdin (1% silver sulfadiazine) in vivo on Wistar rats. Burns were generated on the back of the rats and at predetermined time intervals tissue samples were collected and evaluated histologically. The analyses showed that chitosan based gel formulations containing Egg Yolk Oil (E1) and chitosan based gel formulations containing EYO and EGF (M1) formulations seem to be better alternatives for Silverdin with a significant difference (p < 0.05) considering healing ranks of tissue samples.


Asunto(s)
Quemaduras/tratamiento farmacológico , Quitosano/química , Quitosano/uso terapéutico , Yema de Huevo/química , Factor de Crecimiento Epidérmico/química , Factor de Crecimiento Epidérmico/uso terapéutico , Administración Cutánea , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/química , Quemaduras/patología , Química Farmacéutica , Estabilidad de Medicamentos , Femenino , Geles , Concentración de Iones de Hidrógeno , Ratas , Ratas Wistar , Reología , Sulfadiazina/administración & dosificación , Sulfadiazina/química , Cicatrización de Heridas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA